Docetaxel SUN
On 6 June 2016, Sun Pharmaceutical Industries Europe B.V. officially notified theCommittee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Docetaxel Sun, for the treatment of various types of cancer.
Click on this link for more information.
